Basket Updated
0
Items added
Jan 2013, CST granted patent for PCR Methods for detection of a subset of treatable non-small cell lung cancers.
Cell Signaling Technology, Inc. Announces License in Personalized Cancer Diagnostics.
Mass spectrometry-based proteomic methods like PTMScan can be applied in translational research. For example to identify novel biomarkers of disease
July 2013, CST awarded patents critical to lung cancer therapy. Secures dominant IP position for EML4-ALK in NSCLC that spans from research through diagnosis and therapy.
PTMScan Discovery in Translational Research (A Case Study)
July 2011, CST granted Patent License to Pfizer under the patent estates pooled by CST and Astellas Pharma, Inc. (Patent Estates) relating to EML4 anaplastic lymphoma kinase (ALK).
Cell Signaling Technology, Inc. (CST) of Danvers, MA, announced today that it has introduced a highly specific PD-L1 rabbit monoclonal antibody (mAb).
Cell Signaling Technology, Inc. Announces Introduction of Antibody Important to Breast Cancer Research.
PTMScan Technology enables biomarker discovery and signaling regulation by combining enrichment of post-translational modifications with mass spectrometry.
Jan 2012, Ventana to collaborate with Pfizer & CST on companion diagnostic to identify lung cancer patients with ALK gene rearrangements.
Identification of ALK and ROS1 fusion proteins in non-small cell lung cancer (NSCLC) at Cell Signaling Technology.
Expert-reviewed interactive signaling pathways providing current overviews of the regulation of actin and microtubule dynamics, as well as links to products from CST.
Scientific posters presented by CST scientists at various conferences and trade shows through the years.
